DEVELOPMENT OF ANTI-VIF COMPOUNDS

$68,415P51FY2011RRNIH

Harvard Medical School, Boston MA

Investigators

Linked publications & trials

Paper 36366153 Paper 33657166 Paper 32393800 Paper 32001079 Paper 30652349 Paper 30502901 Paper 29720564 Paper 29635114 Paper 29496145 Paper 29460723 Paper 29344862 Paper 29256819 Paper 28973854 Paper 28792003 Paper 28747495 Paper 28671063 Paper 28228258 Paper 28170189 Paper 27683750 Paper 27559102 Paper 27544476 Paper 27435105 Paper 26596587 Paper 26585218 Paper 26185285 Paper 26129855 Paper 25915761 Paper 25877746 Paper 25732245 Paper 25732063 Paper 25707797 Paper 25688559 Paper 25479017 Paper 25468404 Paper 25308086 Paper 25282469 Paper 25143442 Paper 25135832 Paper 25011105 Paper 25010769 Paper 24899503 Paper 24702501 Paper 24628518 Paper 24489878 Paper 24447378 Paper 24416083 Paper 24411773 Paper 24399297 Paper 24335292 Paper 24330519 Paper 24172905 Paper 24163808 Paper 24109219 Paper 24098278 Paper 24069471 Paper 24056786 Paper 24027336 Paper 23737549 Paper 23725361 Paper 23723737 Paper 23696734 Paper 23666606 Paper 23637396 Paper 23615116 Paper 23588085 Paper 23527882 Paper 23499489 Paper 23483986 Paper 23472105 Paper 23459687 Paper 23403573 Paper 23357301 Paper 23354533 Paper 23303046 Paper 23300447 Paper 23290931 Paper 23280047 Paper 23269489 Paper 23256740 Paper 23211411 Paper 23209422 Paper 23185133 Paper 23154262 Paper 23152518 Paper 23135296 Paper 23126673 Paper 23099234 Paper 23085363 Paper 23051916 Paper 23028326 Paper 22993152 Paper 22969429 Paper 22948980 Paper 22933282 Paper 22927823 Paper 22815535 Paper 22778226 Paper 22734618 Paper 22711907 Paper 22653975

Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. In this project we propose the development of small molecule inhibitors of the HIV Vif protein. While Vif has been recognized as an important gene for viral infectivity, the cellular mechanism responsible for this effect has only recently been elucidated. Vif functions to inactivate the cellular defense protein APOBEC 3G which otherwise induces deamination of viral DNA rendering it noninfectious. Our previous work in vaccine development has demonstrated the crucial in vivo significance of Vif to viral replication in the rhesus macaque and supports the relevance of this drug target. The University of Massachusetts Medical School (UMMS) established a high throughput drug screening facility in order to identify lead compounds with activity against HIV/SIV Vif. As part of this venture, a large chemical library has been screened for anti-Vif compounds using a cell-based inhibitor screen and a number of lead compounds have been identified that have the potential to target peripheral and CNS reservoirs of HIV-1 replication and persistence. The proposed work will facilitate the further development of these Vif inhibiting agents. Rodent and nonhuman primate studies will use a three tier approach consisting of: 1) toxicity and pharmacokinetic studies to define drug candidate dose, vehicle and route;2) short term efficacy studies to evaluate effect on peripheral viral load;and 3) long term efficacy studies to evaluate the effect on SIV encephalitis.

View original record on NIH RePORTER →